Market Outlook
Rapid growth in China's approved PCSK9 inhibitor market favors Hasten Biopharmaceuticals' licensing position for Lerodalcibep in Greater China. The market was approximately RMB 3 billion in 2024, when revenue rose 95% year over year, and a Frost & Sullivan forecast places it at approximately RMB 10 billion in 2030; Everest Medicines holds the exclusive Greater China license for Lerodalcibep, with rights to develop, register, and commercialize it and to use Hasten Biopharmaceuticals' trademarks for the product.
An estimated 400 million individuals in China have dyslipidemia, and only about 14% receive lipid-lowering treatment.
Risk Factors
Deal completion and regulatory timing are the main risks to Hasten Biopharmaceuticals' growth, because its commercialization services agreement must still clear customary closing conditions before the expected close in the first half of 2026, while the licensing agreement closes immediately. The potential approval of Lerodalcibep in Greater China in 2027 is expected to contribute to future revenue growth within Everest's cardiovascular portfolio.
Hasten Biopharmaceuticals pays Everest Medicines service fees equal to 20% to 55% of each product's quarterly net sales, a cost structure tied to the six approved and commercially available products across three major therapeutic areas covered by the commercialization services agreement.
Hasten Biopharmaceuticals plans to use the fundraising proceeds to fund future acquisitions and business development of innovative pipeline assets.
Product Overview
Hasten Biopharmaceuticals sells approved prescription medicines for chronic cardiovascular and metabolic disease—including hypertension and diabetes—and for critical care, delivered through owned marketing authorizations and a commercialization arrangement with Everest Medicines that covers six approved, commercially available products across three major therapeutic areas.
The critical care portfolio includes Rocephin and Stilamin. Under the agreement, Everest Medicines provides commercialization support for Hasten Biopharmaceuticals' mature asset portfolio using its existing sales and marketing organization. Hasten Biopharmaceuticals pays Everest Medicines service fees of 20% to 55% of the quarterly net sales for each product.
The Celltrion agreement grants Hasten Biopharmaceuticals Marketing Authorization Holder rights for the acquired products across eight countries and regions, including South Korea, Singapore, Thailand, Australia and China Hong Kong S.A.R.
